Skip to main content
Top
Published in: Dermatology and Therapy 5/2024

Open Access 04-05-2024 | Atopic Dermatitis | Original Research

Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study

Authors: Spyridon Gkalpakiotis, Susanna Kannenberg, Külli Kingo, Hanan Rabea Nada, Margarita R. Rakhmatulina, Aleksandra Lesiak, Alin C. Nicolescu, Razvigor Darlenski, Alaa Masri, Limei Zhou, Teotonio Albuquerque, Shereen Hammad, Iman Almasry

Published in: Dermatology and Therapy | Issue 5/2024

Login to get access

Abstract

Introduction

Limited real-world evidence exists about the burden of atopic dermatitis (AD) in patients receiving systemic or non-systemic therapies in clinical practices. ESSENTIAL AD was an observational study that aimed to fill this information gap.

Methods

ESSENTIAL AD enrolled (September 2021–June 2022) adult patients with physician-confirmed AD that was routinely managed with systemic and non-systemic treatment in a real-world setting from 15 countries in Eastern Europe, the Middle East, and Africa. Primary outcome variables were Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI) assessed during one office visit.

Results

A total of 799 enrolled patients fulfilled selection criteria and were included in the study. Patients mean (standard deviation [SD]) age was 36.3 (14.4) years, 457 (57.2%) were female, and the majority of patients were white (647 [81.0%]). Mean (SD) time since AD diagnosis was 17.6 (15.2) years (median 16.5; interquartile range [IQR] 3.3–26.8). The mean (SD) EASI, SCORAD, and DLQI total scores were 11.3 (11.3 [median 8.1; IQR 3.6–15.8]), 37.8 (17.9 [median 35.5; IQR 24.2–49.0]), and 10.6 (7.2 [median 10.0; IQR 5.0–15.0]), respectively. Patients receiving systemic treatment had significantly higher disease burden (mean [SD] EASI 13.3 [13.0]; median [IQR] 9.6 [3.9–17.9]) versus non-systemic treatment (mean [SD] 9.3 [8.7]; median [IQR] 6.8 [3.0–13.2]; P < 0.0001). Results were similar for SCORAD (39.9 [19.6] vs 35.6 [15.7]; median [IQR] 38.6 [24.7–53.1] vs 32.6 [23.9–44.6]; P = 0.0017), and DLQI total scores (11.4 [7.4] vs 9.9 [6.9]; median [IQR] 11.0 [5.0–16.0] vs 9.0 [5.0–14.0]; P = 0.0033, respectively).

Conclusion

Patients with AD continue to have substantial disease burden despite treatment with systemic therapy, suggesting that a need for effective disease management remains, including effective therapies that improve psychological outcomes and reduce economic burden of AD, in Eastern Europe, the Middle East, and Africa.
Appendix
Available only for authorised users
Literature
1.
go back to reference Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30.CrossRefPubMed Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30.CrossRefPubMed
2.
go back to reference Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52. Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.
3.
go back to reference Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–33.CrossRefPubMedPubMedCentral Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–33.CrossRefPubMedPubMedCentral
4.
go back to reference Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340–35. Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340–35.
5.
go back to reference Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–78.CrossRefPubMed Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–78.CrossRefPubMed
6.
go back to reference Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–12.CrossRefPubMedPubMedCentral Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–12.CrossRefPubMedPubMedCentral
7.
go back to reference de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–36.CrossRefPubMedPubMedCentral de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–36.CrossRefPubMedPubMedCentral
8.
go back to reference Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300.CrossRefPubMedPubMedCentral Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300.CrossRefPubMedPubMedCentral
9.
go back to reference Han Y, Woo YR, Cho SH, Lee JD, Kim HS. Itch and Janus kinase inhibitors. Acta Derm Venereol. 2023;15(103):adv00869. Han Y, Woo YR, Cho SH, Lee JD, Kim HS. Itch and Janus kinase inhibitors. Acta Derm Venereol. 2023;15(103):adv00869.
10.
go back to reference Al Hammadi A, Pakran J, Farghaly M, et al. Healthcare resource utilization and direct cost of patients with atopic dermatitis in Dubai, United Arab Emirates: a retrospective cohort study. Dermatol Ther (Heidelb). 2022;19:1–25. Al Hammadi A, Pakran J, Farghaly M, et al. Healthcare resource utilization and direct cost of patients with atopic dermatitis in Dubai, United Arab Emirates: a retrospective cohort study. Dermatol Ther (Heidelb). 2022;19:1–25.
11.
go back to reference Elezbawy B, Fasseeh AN, Fouly E, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region. Dermatol Ther (Heidelb). 2023;13(1):131–46.CrossRefPubMed Elezbawy B, Fasseeh AN, Fouly E, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region. Dermatol Ther (Heidelb). 2023;13(1):131–46.CrossRefPubMed
Metadata
Title
Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study
Authors
Spyridon Gkalpakiotis
Susanna Kannenberg
Külli Kingo
Hanan Rabea Nada
Margarita R. Rakhmatulina
Aleksandra Lesiak
Alin C. Nicolescu
Razvigor Darlenski
Alaa Masri
Limei Zhou
Teotonio Albuquerque
Shereen Hammad
Iman Almasry
Publication date
04-05-2024
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 5/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-024-01146-8

Other articles of this Issue 5/2024

Dermatology and Therapy 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare